NUCC-0226272, a potent PROTAC, induces the degradation of EZH2 and exhibits anti-proliferative effects. It holds promise for application in cancer research [1].

NUCC-0226272（0.01-10 μM；5 天）对 LNCaP 和 22Rv1 细胞表现出抗增殖作用 [1]。NUCC-0226272（10 μM；6 天）显著降解 EZH2，减少 PRC2 成分 SUZ12，并降低 C4-2B 细胞中 H3K27me3 的水平 [1]。

Pharmacokinetic parameters of NUCC-0226272 in C57Bl/6 mice [1] are as follows: after an IP dose of 4 mg/kg, T_max is 0.83 hours, C_max reaches 3650 ng/mL, AUC_last is 12777389 min·ng/mL, t_1/2 is 3.46 hours, clearance (CL) is 3.11 mL/min/kg, and volume of steady-state distribution (V_ss) is 3.11 L/kg.